The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease

September 2, 2010 updated by: Forest Laboratories

Efficacy and Tolerability of Nebivolol Compared With Carvedilol in Patients With Coronary Artery Disease and Stage I or II Hypertension

This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery disease.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
39

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • Forest Investigative Site
    • Arizona
      • Peoria, Arizona, United States, 85381
        • Forest Investigative Site
    • California
      • Buena Park, California, United States, 90620
        • Forest Investigative Site
      • Los Angeles, California, United States, 90048
        • Forest Investigative Site
      • Orange, California, United States, 92868
        • Forest Investigative Site
      • Santa Ana, California, United States, 92705
        • Forest Investigator Site
    • Connecticut
      • Guilford, Connecticut, United States, 06437
        • Forest Investigative Site
    • Florida
      • Coral Gables, Florida, United States, 33134
        • Forest Investigator Site
      • Daytona Beach, Florida, United States, 32117
        • Forest Investigative Site
      • Hollywood, Florida, United States, 33021
        • Forest Investigator Site
      • New Smyrna Beach, Florida, United States, 32168
        • Forest Investigator Site
      • Orlando, Florida, United States, 32803
        • Forest Investigative Site
      • Winter Haven, Florida, United States, 33880
        • Forest Investigator Site
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Forest Investigative Site
    • Indiana
      • Indianapolis, Indiana, United States, 46254
        • Forest Investigator Site
    • Louisiana
      • Lafayette, Louisiana, United States, 70503
        • Forest Investigator Site
    • Maine
      • Auburn, Maine, United States, 04210
        • Forest Investigator Site
    • Massachusetts
      • Pittsfield, Massachusetts, United States, 01201
        • Forest Investigative Site
      • Worcester, Massachusetts, United States, 01655
        • Forest Investigator Site
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Forest Investigative Site
      • Lansing, Michigan, United States, 48910
        • Forest Investigative Site
    • Nevada
      • Las Vegas, Nevada, United States, 89119
        • Forest Investigator Site
    • New York
      • Bronx, New York, United States, 10451
        • Forest Investigative Site
      • Bronx, New York, United States, 10468
        • Forest Investigative Site
      • Northport, New York, United States, 11768
        • Forest Investigative Site
    • North Carolina
      • Charlotte, North Carolina, United States, 28211
        • Forest Investigative Site
      • Lenoir, North Carolina, United States, 28645
        • Forest Investigator Site
    • North Dakota
      • Fargo, North Dakota, United States, 58103
        • Forest Investigative Site
    • Ohio
      • Cincinnati, Ohio, United States, 45219
        • Forest Investigative Site
    • Pennsylvania
      • Lancaster, Pennsylvania, United States, 17603
        • Forest Investigative Site
    • South Carolina
      • Charleston, South Carolina, United States, 29401
        • Forest Investigative Site
      • Florence, South Carolina, United States, 29501
        • Forest Investigator Site
    • Tennessee
      • Cleveland, Tennessee, United States, 37312
        • Forest Investigative Site
    • Texas
      • Carrollton, Texas, United States, 75006
        • Forest Investigative Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female ambulatory outpatients 18 to 85 of age at screening
  • Coronary artery disease as defined by: status post myocardial infarction (heart attack) greater than 14 days post event with no upper time limit (and followed by stress testing with additional imaging (echocardiographic or nuclear) within the 12 months prior to enrollment) and/or angiographic evidence of one or more major coronary arteries narrowing of greater than 50% and/or a history of percutaneous or surgical coronary revascularization greater than 4 months after that procedure at the time of enrollment.
  • Qualifying blood pressure criteria for study entry and for randomization
  • Willing to adhere to exercise stress (treadmill) tests

Exclusion Criteria:

  • Unstable angina within 7 days of screening
  • Potential coronary surgical/intervention within the next 6 months
  • Have any form of secondary hypertension
  • Have a history of hypersensitivity to nebivolol, metoprolol, carvedilol, or any beta blocker

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
ACTIVE_COMPARATOR: 1
Encapsulated Nebivolol
Drug: Nebivolol
Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
Other Names:
  • Bystolic
ACTIVE_COMPARATOR: 2
Encapsulated Carvedilol
Drug: Carvedilol
Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
Other Names:
  • Coreg

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Peripheral Diastolic Blood Pressure (DBP)
Time Frame: 18 weeks post initiation of randomized treatment
Peripheral diastolic blood pressure (DBP) at post-baseline (visit 13, week 18)
18 weeks post initiation of randomized treatment

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Peripheral Systolic Blood Pressure (SBP)
Time Frame: 18 weeks post initiation of randomized treatment
Peripheral systolic blood pressure (SBP) at visit 13 (week 18)
18 weeks post initiation of randomized treatment
Proportion of Patients With Peripheral SBP <140 mm Hg and DBP <90 mm Hg at Week 18
Time Frame: 18 weeks post-treatment
Proportion of Patients with Peripheral SBP <140 mm Hg and DBP <90 mm Hg at Week 18
18 weeks post-treatment
Left Ventricular Ejection Fraction (LVEF) (%) at Week 18
Time Frame: 18 weeks post-treatment
Left ventricular ejection fraction (LVEF) (%) at Week 18
18 weeks post-treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Forest Laboratories

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Tatjana Lukic, MD., M.Sc, Forest Research Institute, Inc., a Subsidiary of Forest Laboratories, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 1, 2008

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 1, 2009

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 29, 2008

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 1, 2008

First Posted (ESTIMATE)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 7, 2008

Study Record Updates

Last Update Posted (ESTIMATE)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 28, 2010

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 2, 2010

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NEB-MD-06

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings